Treatment of lung fibrosis in systemic rheumatic diseases (new treatment)

Z Rheumatol. 2021 Sep 10:1-12. doi: 10.1007/s00393-021-01067-3. Online ahead of print.ABSTRACTAn interstitial lung disease represents a relevant organ manifestation in many systemic rheumatic diseases (connective tissue disease-interstitial lung disease, CTD-ILD). In 10% of the cases pulmonary fibrosis even results in an underlying systemic disease. The CTD-ILDs are frequently associated with a poor prognosis. Therefore, it is important to test patients with systemic rheumatic diseases timely and regularly for the presence of an ILD. Treatment decisions should be made together with pneumologists and rheumatologists, particularly with respect to the initiation of a specific treatment. Treatment is based on randomized studies only in a few cases and can mostly be derived from case control studies. For systemic sclerosis-associated ILD (SSc-ILD) antifibrotic treatment with nintedanib has also now been approved in addition to an immunosuppressive treatment. For other CTD-ILDs an antifibrotic treatment should be discussed in an interdisciplinary approach depending on the underlying disease corresponding to a progressively fibrosing ILD.PMID:34505934 | PMC:PMC8429885 | DOI:10.1007/s00393-021-01067-3
Source: Zeitschrift fur Rheumatologie - Category: Rheumatology Authors: Source Type: research